PRIMARY STUDY
Case reports of identical twins with developmental and epileptic encephalopathy with STXBP1 gene mutations for whom different CBD supplementations were markedly effective
Key Findings: This case report of a set of twins with developmental and epileptic encephalopathy with STXBP1 gene mutation who both responded exceptionally well to two different add-on regimens of cannabidiol (CBD).
Type of Study: Clinical Trial
Study Sample Size: 2
Study Result: Positive
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromenic Acid (CBC-a), Cannabigerolic Acid (CBG-a), Pharma CBD, Tetrahydrocannabivarin (THCV), Cannabitriol (CBT)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Terpenes Studied: ß-Caryophyllene, Bisabolol
Receptors Studied: GPCR 55
Ligands Studied: GABA
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion), Sublingual/Oromucosal
Cannabinoid Ratio: (CBD : Pharma CBD) 1 : 1 
Dosage Form: CBD Supplement (1): 993.50mg/g 99.35% CBD Supplement (2): 704.30mg/g 70.43%
Starting Dose: Twin 1: CBD supplement at 4 mg/kg/day Twin 2: CBD supplement at 2 mg/kg/day
Titration: Twin 2: titrated up weekly by 2 mg/kg/day
Maximum Dose: Twin 1: 400 mg/day Twin 2: 600 mg/day
Clinical Relevance: Monozygotic twins achieved seizure suppression with CBD supplements containing different ingredients.
Additional Notes: Parallel Dose Comparison, Dose Titration, Dose Escalation
Link to study
Authors: Masataka Y, Miki N, Akino K, Yamamoto H, Takumi I
Journal: Case reports of identical twins with developmental and epileptic encephalopathy with STXBP1 gene mutations for whom different CBD supplementations were markedly effective.
Year of Pub: 2024
Research Location(s): Japan
Citation: Masataka Y, et al. Case reports of identical twins with developmental and epileptic encephalopathy with STXBP1 gene mutations for whom different CBD supplementations were markedly effective. Epilepsy Behav Rep. 2024; 28:100720. doi: 10.1016/j.ebr.2024.100720
